Sugammadeks

Year 2015, Volume: 16 Issue: 4, 273 - 278, 31.03.2016

Tayfun Et

Abstract

Genel anestezide steroid yapıdaki nöromüsküler bloker ajanlar (NMBA); hızlı ve kolay endotrakeal entübasyon ve ventilasyon uygulamasındaki etkilerinden dolayı kullanımı artmaktadır. NMBA’ın kullanımından kaynaklanan postoperatif rezidüel blok; hipoventilasyon, havayolu obstrüksiyonu, hipoksi ve ölüm gibi komplikasyonlara neden olmaktadır. Sugammadeks steroid yapıda NMBA’ın etkisini geri çeviren, gamma-siklodektrin yapıda ve sekiz glukoz molekülü içeren ilk seçici bağlayıcı ajandır. Sugammadeks uygulamasının kolay, etkisinin yüksek ve hızlı olması ve yan etkisinin az olması sebebiyle kullanımı yaygınlaşmaktadır. Sugammadeksin yapısı, uygulama dozu, yan etkisi ve terapotik etkisi hakkında bilği vermeyi amaçladık.

Keywords

Nöromüsküler bloker, postoperatif rezidüel blok, sugammadeks

References

• Caldwell JE. Clinical limitations of acetylcholinesterase antagonists. J Crit Care 2009;24(1):21-8.
• Srivastava A, Hunter JM. Reversal of neuromuscular block. Br J Anaesth 2009;103(1):115-2.
• Adam JM, Bennett DJ, Bom A. Cyclodextrin-derived host molecules as reversal agents for the neuromuscular blocker rocuronium bromide: synthesis and structure- activity relationships. J Med Chem 2002;45(9):1806-16.
• Bom A, Bradley M, Cameron K. A novel concept of reversing neuromuscular block: chemical encapsulation of rocuronium bromide by a cyclodextrin-based synthetichost. Angew Chem Int Ed Engl 2002;4:(2) 266
• Challa R, Ahuja A, Ali J. Cyclodextrins in drug delivery. AAPS Pharm Sci Tech 2005;6(2):329-57.
• Schering-Plough Corp. Bridion_ (sugammadex sodium) injection: first and only selective relaxant binding agent approvedin European Union.http://www. scheringplough.com/schering_plough/news/release. jsp?releaseID=1180933 Erişim: 23.05.2013.
• Stair C, Fernandez-Bustamante A. Sugammadex, the first selective relaxant binding agent for neuromuscular block reversal. Drugs Today (Barc) 2012;48(6):405- 13.
• Miller RD. Sugammadex: an opportunity to change the practiceof anesthesiology. Anesth Analg ;104(3):477-8. Rosemary MGH, Rajinder KM. Sugammadex a selective relaxant binding agent for reversal of neuromuskuler block. Neurother 2009;9(5):599-608.
• International Conference on harmonisation of technical requirements for registration of pharmaceuticals for human use. The clinical evaluation of QT/QTc interval prolongation and proarrhythmic potential for non- anti arrhythmic drugs. http://www.ich.org/LOB/media/ MEDIA1476. Erişim 30.04.2013.
• European Medicines Agency. Bridion (sugamma- dex sodium) 100 mg/mL: http://www.emea.europa.eu/ humandocs/PDFs/EPAR/bridion/H-885-PI-en. Erişim 03.2013.
• Staals LM, Snoeck MMJ, Driessen JJ, et al. Multicentre, parallel-group, comparative trial evaluating the efficacy and safety of sugammadex in patients with end-stage renal failure ornormal renal function. Br J Anaesth ;101(4):492-7. Gijsenbergh F, Ramael S, Houwing N, et al. First humanexposure of Org 25969, a novel agent to reverse the actionof rocuronium bromide. Anesthesiology ;103(4):695-703.
• Plaud B, Meretoja O, Hofmockel R, et al Reversal of rocuronium-induced neuromuscular blockade with sugammadexin pediatric and adult surgical patients. Anesthesiology 2009;110(2):284-94.
• Sparr HJ, Vermeyen KM, Beaufort AM, et al. Early reversalof profound rocuronium-induced neuromuscular blockade by sugammadex in a randomized multicenter study: efficacy, safety, and pharmacokinetics. Anesthesiology 2007;106(5):935-43.
• Blobner M, Eriksson L, Scholz J, et al. Reversal of rocuronium-induced neuromuscular blockade with sugammadex compared with neostigmine during sevoflurane anaesthesia: results of a randomised, controlled trial. Eur J Anaesthesiol 2010;27(10):874-81.
• Sorgenfrei IF, Norrild K, Larsen PB, et al. Reversal of rocuronium-induced neuromuscular block by the selective relaxant binding agent sugammadex: a dose- finding andsafety study. Anesthesiology 2006;104(4):667- de Boer HD, Driessen JJ, Marcus MAE, et al.
• Reversal ofrocuronium-induced (1.2 mg/kg) profound neuromuscular block by sugammadex: a multicenter, dose-finding and safety study. Anesthesiology ;107(2):239-44. Organon USA. FDA Anesthetic and Life Support Advisory Committee Meeting: briefing document (background package) for sugammadex sodium injection:http://www.fda.gov/ohrms/dockets/ac/08/ briefing/2008-4346b1-02-Organon. Erişim 11.06.2013.
• Jones RK, Caldwell JE, Brull SJ, et al. Reversal of profound rocuronium-induced blockade with sugammadex: a randomized comparison with neostigmine. Anesthesiology 2008;109(5):816-24.
• Flockton EA, Mastronardi P, Hunter JM, et al. Reversal of rocuronium-induced neuromuscular block with sugammadexis faster than reversal of cisatracurium- induced block with neostigmine. Br J Anaesth ;100(5):622-30. Lee C, Jahr JS, Candiotti KA, et al. Reversal of profound neuromuscular block by sugammadex administered 3 minutes after rocuronium: a comparison with spontaneous recovery from succinylcholine. Anesthesiology 2009;110(5):1020-5.
• Molina AL, de Boer HD, Klimek M, et al. Reversal of rocuronium-induced (1.2mg kg-1) profound neuromuscular block by accidental high dose of sugammadex (40 mg kg-1). Br J Anaesth 2007;98(5):624
• Khuenl-Brady KS, Wattwil M, Vanacker BF, et al. Sugammadex provides faster reversal of vecuronium- induced neuromuscular blockade compared with neostigmine: a multicenter, randomized, controlled trial. Anesth Analg 2010;110(1):64-73.